Filing Analysis
Oramed Pharmaceuticals has entered into an extension agreement with Scilex Holding Company to delay the repayment of approximately $36.2 million in outstanding note obligations. The agreement includes a structured cash payment schedule and a contingency clause involving stock conversion if payments are not met by September 30, 2026.
🚩 Red Flags
- Significant debt owed by a counterparty (Scilex) that requires multiple extensions, indicating potential liquidity issues for the debtor.
- The 'clawback' nature of the extension fee ($1.5M deemed earned if default occurs) suggests high risk in Scilex's ability to repay.
- Potential dilution/volatility risk if Oramed is forced to accept Scilex common stock instead of cash.
📋 Key Facts
- Total Note Obligations from Scilex include ~$29.5M (Tranche A) and ~$6.7M (Tranche B).
- An extension fee of $1 million was previously agreed upon; $0.5 million was received on June 25, 2026.
- Scilex to pay $5 million by July 31, 2026.
- Remaining balance due in full by September 30, 2026.
- If Scilex fails to pay by the Due Date, the first $1.5M received is deemed a non-refundable extension fee and not applied to principal/interest.
- Failure to meet the deadline triggers a provision where remaining obligations can be satisfied via delivery of Scilex common stock.
Oramed Pharmaceuticals completed the sale of its subsidiary Oratech Pharma to Lifeward Ltd. in exchange for equity, warrants, and a revenue-sharing agreement. Simultaneously, Oramed invested $9 million into Lifeward through senior secured convertible notes.
🚩 Red Flags
- The revenue-sharing agreement terminates if Lifeward's market capitalization reaches $200 million, potentially capping the upside of the disposition.
- Concentration risk: Oramed is heavily tying its value to the performance and equity of Lifeward Ltd.
📋 Key Facts
- The transaction closed on March 25, 2026.
- Oramed sold 100% of Oratech Pharma, Inc. to Lifeward Ltd.
- Consideration included 1,250,363 Lifeward Ordinary Shares and 1,006,113 pre-funded warrants, representing up to 49.99% of Lifeward's fully diluted equity.
- Oramed will receive 4% revenue sharing on Lifeward's ReWalk Personal Exoskeleton products, capped by time (10 years) or a $200M market cap trigger.
- Oramed purchased $9,000,000 in senior secured convertible notes from Lifeward with a conversion price of $5.40 per share.
- Oramed received additional warrants to purchase 1,296,296 shares and 1,666,666 shares at $5.40 per share.
Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company on February 19, 2026, receiving warrants to purchase 100,000 shares of Scilex common stock at $20.00/share in exchange for deferring an amortization payment on Scilex's Tranche B Notes. The deferred payment was subsequently made in November 2025, and the warrants expire December 13, 2029.
🚩 Red Flags
- Oramed's ongoing financial entanglement with Scilex, which has faced significant financial difficulties — the need for warrant compensation to defer a scheduled debt payment suggests Scilex liquidity stress
- The exercise price of $20.00/share with an anti-dilution floor of $8.22 suggests market expectation of potential Scilex dilution events
- The amortization payment originally due October 2025 was deferred and not paid until November 2025, indicating Scilex payment difficulties
- Cashless exercise fallback provision suggests uncertainty about Scilex's ability to maintain effective registration statements
- Related-party complexity: Oramed holds Senior Secured Convertible Notes in Scilex and now warrants, creating layered exposure to Scilex credit risk
📋 Key Facts
- Oramed received warrants to purchase 100,000 shares of Scilex (SCLX) common stock at $20.00/share exercise price
- Warrants issued in exchange for Oramed deferring an October 1, 2025 amortization payment under Scilex's Senior Secured Convertible Note (Tranche B Notes)
- The deferred amortization payment was made to Oramed in November 2025
- Warrants are immediately exercisable upon issuance with expiration date of December 13, 2029
- Exercise price has anti-dilution protection with a floor price of $8.22
- Beneficial ownership cap of 4.99% (adjustable up to 9.99% with 61 days notice)
- Scilex must file an S-3 (or S-1) registration statement by the later of 30 days post-agreement, 10 days after Scilex's 10-K filing, or March 31, 2026
- Cashless exercise permitted if no effective registration statement exists at time of exercise
- Change-of-control provision entitles Oramed to Black-Scholes value repurchase in cash
- Original Securities Purchase Agreement with Scilex dated October 7, 2024
Oramed Pharmaceuticals entered into a complex series of agreements with Lifeward Ltd. involving the sale of its subsidiary, Oratech Pharma, in exchange for equity and warrants in Lifeward, alongside a $18 million convertible note investment in Lifeward.
🚩 Red Flags
- Significant dilution risk for Lifeward shareholders via warrants and convertible notes.
- Complex, multi-layered deal structure involving subsidiary divestiture and debt investment.
- Contingent nature of the second $9M tranche based on aggressive sales growth targets (150% increase).
📋 Key Facts
- Sale of wholly-owned subsidiary Oratech Pharma to Lifeward Ltd.
- Consideration includes Lifeward Ordinary Shares (up to 45.0% cap), pre-funded warrants, and share purchase warrants.
- Oramed to receive 4% revenue sharing on Lifeward's ReWalk Personal Exoskeleton products for up to 10 years or until a maximum amount is reached.
- Oramed to purchase $9M in senior secured convertible notes (Initial) plus an additional $9M (Additional) if specific milestones are met.
- The 'Additional Notes' closing depends on Lifeward achieving a 150% increase in ReWalk Unit Sales or a stock price >$1.15 for 10 consecutive days.
- Notes bear 8% interest per annum, payable in cash or PIK (payment-in-kind).
- The transaction is subject to Lifeward shareholder approval due to Nasdaq 19.99% issuance rules.
Oramed Pharmaceuticals announced the receipt of an $18 million payment from Scilex Holdings Inc. to satisfy an Option Agreement and declared a cash dividend of $0.25 per share.
📋 Key Facts
- Received $18 million from Scilex Holdings Inc. as full satisfaction of obligations under an Option Agreement.
- Board approved a cash dividend of $0.25 per share.
- Aggregate dividend distribution is approximately $10.5 million.
- Dividend record date: January 16, 2026; Payment date: January 26, 2026.
- Dividend to be funded with surplus capital.
Oramed Pharmaceuticals Inc. announced the resignation of Board member Leonard Sank, effective January 1, 2026. The departure is not due to any disagreement with the company's operations or policies.
🚩 Red Flags
- Loss of long-tenured board member (18 years) may indicate a shift in governance or strategic direction, though no conflict was cited.
📋 Key Facts
- Leonard Sank is resigning from the Board of Directors.
- Resignation becomes effective as of January 1, 2026.
- Mr. Sank has served on the Board for 18 years.
- The company explicitly states the resignation was not due to any disagreement regarding operations, policies, or practices.
Oramed Pharmaceuticals Inc. has completed the second and final tranche of a warrant repurchase agreement with Scilex Holding Company. This transaction concludes a series of repurchases totaling $28.5 million in aggregate payments to Oramed.
📋 Key Facts
- Scilex Holding Company completed the second tranche of a warrant repurchase on December 30, 2025.
- The final tranche involved the repurchase of 3,370,000 shares of Scilex Common Stock for an aggregate price of $14,000,000 (including prepayments).
- A second option fee of $750,000 was paid to Oramed for the final tranche.
- The total aggregate payments received by Oramed from Scilex across both tranches amount to $28,500,000.
- The first tranche, completed on September 30, 2025, involved 3,130,000 shares for $13,000,000 plus a $750,000 fee.
Oramed Pharmaceuticals Inc. filed an 8-K to announce the release of its unaudited financial results for the nine-month period ending September 30, 2025.
📋 Key Facts
- Reporting date: November 17, 2025
- Period covered: Nine months ended September 30, 2025
- Nature of filing: Unaudited financial results announcement via press release (Exhibit 99.1)
Oramed Pharmaceuticals Inc. has declared a dividend of one common stock purchase right (a 'Right') for each outstanding share of common stock. This is a classic 'poison pill' shareholder rights plan designed to prevent hostile takeovers by making an acquisition prohibitively expensive.
🚩 Red Flags
- Implementation of a 'Poison Pill' often indicates management is anticipating a hostile takeover attempt or an unsolicited bid.
- The plan includes provisions that significantly dilute existing shareholders in the event of a change in control (2x market value multiplier).
📋 Key Facts
- Dividend date: November 27, 2025; Record date: November 27, 2025.
- Each Right allows the holder to purchase one share of Common Stock at $10.00 per share.
- The plan is triggered if a person or group acquires 15% or more of the outstanding shares (the 'Acquiring Person').
- Upon triggering, holders (other than the Acquiring Person) can receive common stock with a market value of two times the exercise price.
- Rights expire three years from the date of the agreement unless redeemed or exchanged earlier.
Oramed Pharmaceuticals terminated a Joint Venture Agreement with HTIT Biotech after the partner failed to meet closing conditions. Simultaneously, the company completed a share repurchase of 1,155,367 shares from HTIT Biotech at $2.23 per share.
🚩 Red Flags
- Failure of a strategic joint venture partner to meet closing conditions after multiple extensions.
- Termination of a material agreement involving oral drug delivery technology development.
- Release of unaudited and preliminary financial information (Item 2.02) which may be subject to material adjustment.
📋 Key Facts
- Termination of JV Agreement and Supplemental Agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT Biotech) effective October 23, 2025.
- The termination follows HTIT's failure to satisfy closing conditions originally targeted for April 30, 2025.
- Completed a share repurchase of 1,155,367 common shares from HTIT Biotech at $2.23 per share.
- Total consideration for the repurchase was $2,576,468.41.
- The repurchased shares have been cancelled and retired.
- Company issued a shareholder letter containing unaudited, preliminary financial information as of September 30, 2025.
Oramed Pharmaceuticals Inc. announced the completion of the first tranche of a warrant repurchase agreement with Scilex Holding Company. As part of this transaction, Scilex repurchased 3,130,000 warrants for $13,000,000.
📋 Key Facts
- Scilex Holding Company repurchased 3,130,000 warrants on September 30, 2025.
- The first tranche payment to Oramed was $13,000,000.
- A second tranche remains: Scilex has the option to repurchase the remaining 3,370,000 warrants for $14,000,000 on or before December 31, 2025.
- The total aggregate purchase price for all warrants under the Option Agreement is $27,000,000.
Oramed Pharmaceuticals Inc. reported the results of its 2025 Annual Meeting of Stockholders held on August 19, 2025. The meeting included the re-election of several directors and the approval of an amendment to the company's 2019 Stock Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Stockholders approved an amendment to the Amended and Restated 2019 Stock Incentive Plan, increasing authorized shares under the plan by 2,000,000 to a total of 9,500,000 shares.
- Seven directors were re-elected to hold office until the next annual meeting or their respective successors are elected/qualified.
- Stockholders ratified Kesselman & Kesselman (a member of PwC International Limited) as the independent registered public accounting firm for fiscal year 2025.
- The amendment to the Stock Incentive Plan was approved with 12,254,197 votes 'For' and 2,106,100 votes 'Against'.
Oramed Pharmaceuticals entered into an Option Agreement with Scilex Holding Company allowing Scilex to repurchase $27 million worth of warrants in two tranches. The agreement includes a $1.5 million option payment to Oramed and offers Scilex the benefit of extending a senior secured note maturity date if the repurchase is completed.
🚩 Red Flags
- The agreement involves a significant restructuring of debt/warrant terms linked to a senior secured note (Tranche A Note) totaling $101,875,000.
- Complexity regarding warrant exercise prices following Scilex's reverse stock split suggests potential for future dilution or valuation volatility.
📋 Key Facts
- Oramed entered into an Option Agreement with Scilex on July 22, 2025.
- Scilex has the option to repurchase Subject Warrants for a total of $27,000,000 in two tranches: $13M by Sept 30, 2025, and $14M by Dec 31, 2025.
- Oramed receives an upfront option payment of $1,500,000, payable in two equal installments (by Aug 8 and Dec 16, 2025).
- If the repurchase is completed, Scilex's Tranche A Note maturity date extends to March 31, 2026.
- The filing clarifies that Penny Warrants held by Oramed did not adjust following Scilex's 1-for-35 reverse stock split on April 15, 2025, maintaining an exercise price of $0.01 per share.
Oramed Pharmaceuticals Inc. has authorized a one-year extension of its existing stock buyback program. The program allows for the repurchase of up to $20,000,000 in common stock and is now set to expire in June 2026.
📋 Key Facts
- Board of Directors authorized a one-year extension of the current stock buyback program on May 21, 2025.
- The maximum value for repurchases remains at $20,000,000.
- As of May 21, 2025, $2,494,000 in shares have already been repurchased under the previous authorization.
- The program is now scheduled to expire in June 2026.
Oramed Pharmaceuticals (via its subsidiary Oramed Ltd.) has entered into a $36.9 million agreement to acquire a significant stake in Alpha Tau Medical Ltd. through a registered direct offering. Additionally, the company entered into a strategic IR/PR services agreement with Alpha Tau involving non-refundable fees and warrants.
🚩 Red Flags
- Related-party/Interconnected transaction: The acquisition is paired with a service agreement where the target company (Alpha Tau) pays the acquirer (Oramed), which can sometimes be used to offset acquisition costs or manipulate cash flow profiles.
- The IR/PR warrants are issued as restricted securities and involve significant potential dilution for Alpha Tau.
📋 Key Facts
- Oramed acquired 14,110,121 shares of Alpha Tau Medical Ltd. at $2.612 per share.
- Total purchase price for the equity stake is approximately $36.9 million.
- The transaction closed on April 28, 2025.
- Oramed has the right to nominate two directors to Alpha Tau's Board of Directors (subject to conditions).
- Alpha Tau will pay Oramed a total non-refundable fee of $3,000,000 for strategic IR/PR services over three years.
- The service agreement includes warrants for up to 2,390,000 shares at $3.90 and 847,000 shares at $3.474.
Oramed Pharmaceuticals entered into a complex series of agreements with Scilex Holding Company and institutional investors involving royalty purchase rights for Gloperba and Elyxyb products. These transactions include the creation of a royalty interest, security interests in material contracts/IP, and a new licensing structure via a subsidiary (Licensee) to manage international rights.
🚩 Red Flags
- Complex restructuring of debt/royalty obligations involving multiple institutional investors and subsidiaries.
- Subordination of existing liens (Acquiom Agency Services LLC) to new royalty purchasers.
- High complexity of inter-company transactions between Oramed, Scilex, and the BVI-based Licensee.
📋 Key Facts
- Entered into 'G/E Royalty Purchase Agreement' on February 28, 2025, regarding Gloperba and Elyxyb products.
- Oramed is entitled to receive 50.0% of the Purchased Receivables (4% of Scilex/Scilex Pharma net sales worldwide).
- The Royalty Purchase Agreement includes a 'Royalty Security Agreement' where collateral includes collection accounts, material contracts, IP rights, and regulatory approvals.
- A Subordination Agreement was executed, granting first priority liens to the RPA Purchasers over existing debt (Acquiom Agency Services LLC).
- Established a Gloperba License Agreement via 'Licensee' (a BVI company) for worldwide development/commercialization outside the US.
- Scilex is required to facilitate manufacturing introductions and appoint the Licensee as exclusive distributor in the US.
Oramed Pharmaceuticals has finalized a definitive 'Rest of World' license agreement for its ZTlido product through a newly formed entity, RoyaltyVest Ltd. The agreement grants exclusive worldwide rights (outside the US) to develop and commercialize lidocaine-based products, with revenue shared 50/50 between the Licensee and Scilex Pharma.
🚩 Red Flags
- Complex corporate structure involving a BVI-based entity (RoyaltyVest Ltd) and institutional investors, which can sometimes obscure transparency.
- Revenue sharing model requires significant commercialization success to realize value for Oramed.
📋 Key Facts
- Effective Date: February 22, 2025.
- Licensee: RoyaltyVest Ltd (a BVI company formed by LidoDev Institutional Investors).
- Oramed's Stake: Oramed holds a 50% equity interest in the Licensee (RoyaltyVest Ltd) as of Feb 12, 2025.
- Revenue Split: Net Revenue from the 'Lido Licensee Territory' is split 50/50 between RoyaltyVest and Scilex Pharma.
- Exclusivity: RoyaltyVest has exclusive rights to develop/commercialize lidocaine products (including ZTlido) outside the US in designated territories.
- Obligations: Licensee must seek regulatory approval in at least one Major Market Country within 18 months and commit $200,000 annually toward such efforts.
- Parent Guarantee: Scilex Holding Company has provided a guarantee for Scilex Pharma's performance under the agreement.
Oramed Pharmaceuticals entered into a Supplemental Agreement to finalize a joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) involving the formation of 'Oramed NewCo.' The deal includes significant cash investments, asset transfers, and a planned spin-off of Oramed NewCo shares to existing shareholders.
🚩 Red Flags
- Complex corporate restructuring involving asset transfers and spin-offs can create significant execution risk.
- Dependency on Nasdaq listing for the Second Closing to occur by April 30, 2025.
- Potential dilution/complexity regarding the 'Founder Shares' which have veto rights and specific conversion conditions.
📋 Key Facts
- Initial Closing deadline set for April 30, 2025; Second Closing no later than May 31, 2025 (subject to Nasdaq listing).
- HTIT to invest $40 million at Initial Closing and $20 million at Second Closing into Oramed NewCo.
- Oramed Pharmaceuticals and Oramed Ltd. to contribute $7.5 million each at both the Initial and Second Closings.
- Planned 'Spin Off' involving an in-kind distribution of no less than 60% of Oramed NewCo Common Stock to Oramed shareholders.
- Asset Transfer Agreement: Oramed will transfer all rights, titles, and interests in Transferred IP, Business Contracts, and Regulatory Information to Oramed NewCo.
- Oramed is entitled to receive a total of 6,923,076 shares of Oramed NewCo Common Stock as consideration for the Asset Transfer Agreement.
Oramed Pharmaceuticals Inc. has amended its Senior Secured Promissory Note (Tranche A Note) with Scilex Holding Company, extending the maturity date from March 21, 2025, to December 31, 2025. In exchange for this extension, Oramed will receive 3,250,000 shares of Scilex common stock.
🚩 Red Flags
- Extension of debt maturity indicates a need for more time to collect principal, potentially reflecting liquidity constraints at the debtor (Scilex).
- The amendment includes complex 'Cash Sweep Financing' and prepayment waiver options involving Tranche B Notes, suggesting intricate inter-creditor dynamics.
📋 Key Facts
- The Tranche A Note principal amount remaining is $7,675,000 (down from an original $101,875,000).
- Maturity date extended from March 21, 2025, to December 31, 2025.
- Oramed receives 3,250,000 shares of Scilex common stock as consideration for the extension.
- New covenant added: Scilex is prohibited from increasing compensation or incentive equity awards for its officers/directors while the note is outstanding.
Oramed Pharmaceuticals has entered into a deferral and consent agreement regarding its Tranche B Senior Secured Convertible Note with Scilex Holding Company. The agreement defers amortization payments until October 2026 in exchange for a 4% royalty on worldwide net sales of Gloperba and Elyxyb and the delivery of shares.
🚩 Red Flags
- Significant deferral of debt obligations indicates liquidity/repayment pressure from the debtor (Scilex).
- Complexity of the restructuring involving royalties and equity transfers often signals distressed credit conditions.
- Contingent extension required for a separate $25 million promissory note due March 21, 2025.
📋 Key Facts
- The Tranche B Notes have an aggregate principal amount of $50,000,000.
- Amortization payments were originally due to begin January 2, 2025 ($6.25M per quarter).
- Payments are now deferred until October 8, 2026, contingent upon a $1.11 million payment by Scilex to noteholders.
- Noteholders will receive a 10-year, assignable, freely transferable, 4% royalty on worldwide Net Sales of Gloperba and Elyxyb (excluding Canada).
- SCLX JV will deliver 5,000,000 shares of Oramed common stock to noteholders; 2,500,000 are designated for Oramed.
- Noteholders have the option to fund up to 50% of the cash purchase price for Ex-US Product Rights.
Oramed Pharmaceuticals received a $13.2 million payment from Scilex Holding Company toward an upcoming principal installment. This payment, combined with previous installments, satisfies the $15 million due on December 21, 2024.
🚩 Red Flags
- The company is heavily reliant on debt repayments from a single entity (Scilex) to satisfy its own liquidity/receivable needs.
📋 Key Facts
- Received $13,200,000 from Scilex Holding Company on December 13, 2024.
- The payment satisfies the principal installment of $15,000,000 due on December 21, 2024 (when combined with previous payments).
- Aggregate amount repaid or refinanced under Tranche A Note is now $94,200,000.
- Remaining principal owed by Scilex: $7,675,000 under Tranche A Note and $25,000,000 under Tranche B Notes.
Oramed Pharmaceuticals reported a $1 million prepayment received from Scilex Holding Company on October 24, 2024, as part of the ongoing restructuring and repayment of the Tranche A Note. This follows recent refinancing activities involving the issuance of Tranche B Notes to institutional investors.
🚩 Red Flags
- Complex debt restructuring involving multiple tranches (Tranche A and Tranche B) and 'Agreement Among Holders' indicates high financial complexity.
- The company's cash inflows are heavily dependent on the financing activities of a third party (Scilex).
📋 Key Facts
- Received an additional payment of approximately $1,000,000 on October 24, 2024, pursuant to the terms of the Tranche A Note.
- The Tranche A Note requires mandatory prepayments of 70% of net cash proceeds from Scilex's debt or equity financings.
- An aggregate of $80,200,000 of the original principal amount under the Tranche A Note has been repaid or refinanced to date.
- Recent restructuring included a $22,500,000 reduction in Tranche A principal via the issuance of Tranche B Notes and a $2,500,000 reduction via royalty rights exchange.
Oramed Pharmaceuticals entered into a Securities Purchase Agreement to refinance $22.5 million of its existing debt with Scilex Holding Company through the issuance of new senior secured convertible notes. This transaction involves restructuring significant obligations and includes complex conversion terms and warrants.
🚩 Red Flags
- Complex debt restructuring involving senior secured convertible notes which can lead to significant dilution.
- Full-ratchet adjustment feature on the conversion price in connection with subsequent offerings below the current price.
- High default interest rate (15.0%) and a 35% redemption premium for Scilex.
- Cross-default provisions triggered by indebtedness of $5,000,000 or more.
📋 Key Facts
- Date of consummation: October 8, 2024.
- Refinancing amount: $22,500,000 reduction in the principal outstanding balance under the Tranche A Note.
- New instrument: Senior secured convertible notes with an initial principal balance of $25,000,000 and a 10.0% original issue discount.
- Interest rate: 5.5% per annum (increases to 15.0% upon default).
- Maturity: Two-year anniversary from issuance date, subject to extension options.
- Conversion Price: Initial fixed price of $1.09 per share, with a floor of $1.04.
- Warrants: Issuance of 3,750,000 common warrants exercisable at $1.09 for five years.
Oramed Pharmaceuticals Inc. (via its subsidiary Oramed Ltd.) entered into a Master Services Agreement with InClin, Inc. to support an upcoming Phase 3 clinical trial for ORMD-0801.
🚩 Red Flags
- Significant cash outflow ($11.5M) for a single clinical trial phase, which may impact liquidity depending on the company's current cash position.
📋 Key Facts
- Agreement date: September 23, 2024.
- Counterparty: InClin, Inc. (Clinical Research Organization).
- Purpose: Services for a planned Phase 3 clinical trial of ORMD-0801 to assess safety and efficacy in ~300 type 2 diabetic patients.
- Total potential value: Up to approximately $11.5 million.
- Payment structure: Paid over the term of engagement based on monthly hours performed.
- Termination clause: Either party can terminate with 30 days' written notice; breachable with 30-day cure period.
Oramed Pharmaceuticals entered into a Letter Agreement with Scilex Holding Company to restructure debt obligations and receive a $2 million payment. The agreement involves amending liquidity requirements and extending an amortization deadline.
🚩 Red Flags
- Waiver of liquidity requirements (Scilex must maintain $0 liquidity), suggesting significant financial distress or negotiation leverage issues.
- Extension of a large $20M amortization payment by only one week suggests immediate cash flow/repayment pressure.
- The restructuring involves complex warrant exercises and debt application, typical of distressed debt management.
📋 Key Facts
- Scilex agreed to pay Oramed $2,000,000 on September 23, 2024.
- $1,700,000 of the payment will be applied toward the March 21, 2025 amortization due under a $101.875M Senior Secured Promissory Note.
- $300,000 of the payment is for the purchase of 'Purchased Warrants'.
- Scilex's minimum liquidity requirement is waived (set to $0) from September 19, 2024, until the Note's Maturity Date.
- A $20,000,000 amortization payment due on September 23, 2024, has been extended to September 30, 2024.
Oramed Pharmaceuticals Inc. announced the final voting results from its 2024 Annual Meeting of Stockholders held on August 1, 2024. The meeting included the re-election of several directors, an advisory vote on executive compensation, and the ratification of the company's independent auditor.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on August 1, 2024.
- Seven directors were re-elected to hold office until the next annual meeting or until successors are qualified.
- Stockholders approved executive compensation on a non-binding advisory basis (9,171,779 'For' votes).
- Kesselman & Kesselman (member of PwC International Limited) was ratified as the independent registered public accounting firm for the 2024 fiscal year.
Oramed Pharmaceuticals Inc. announced that its Board of Directors has authorized a stock buyback program. The program allows for the repurchase of common stock up to a maximum value of $20,000,000 over the next 12 months.
📋 Key Facts
- Board authorization date: June 26, 2024
- Maximum repurchase amount: $20,000,000
- Program duration: 12 months from authorization
- Repurchase methods include open market transactions or privately negotiated transactions in compliance with Rule 10b-18.
Oramed Pharmaceuticals reported the receipt of a $10.4 million principal payment from Scilex Holding Company on June 20, 2024. This payment fulfills a scheduled installment under the Senior Secured Promissory Note originally entered into in September 2023.
🚩 Red Flags
- The company notes risks regarding 'the Company's ability to obtain payment of principal due pursuant to the Note,' indicating potential counterparty risk or dependency on these inflows for liquidity.
📋 Key Facts
- Received an additional principal payment of approximately $10.4 million on June 20, 2024.
- The payment was applied toward the third principal payment installment under the Scilex SPA Note.
- Total principal payments received from Scilex as of June 20, 2024, amount to $40.0 million.
- The original Senior Secured Promissory Note has a principal amount of $101,875,000 and is due 18 months from its issuance date.
Oramed Pharmaceuticals Inc. announced the appointment of Avraham Gabay as Chief Financial Officer, Treasurer, and Secretary, effective June 18, 2024. Mr. Gabay is a returning executive who previously served in this role for the Company from 2019 to 2021.
📋 Key Facts
- Avraham Gabay appointed as CFO, Treasurer, and Secretary effective June 18, 2024.
- Mr. Gabay previously served as CFO of Oramed from 2019 to 2021.
- Compensation includes a gross monthly salary of NIS 68,000 plus a company car.
- The appointment is governed by an employment agreement with the Company's Israeli subsidiary, Oramed Ltd.
Oramed Pharmaceuticals Inc. announced the resignation of its Chief Financial Officer (CFO), Treasurer, and Secretary, David Silberman, effective July 12, 2024. The company has initiated a search for a successor.
🚩 Red Flags
- Departure of a key C-suite executive (CFO) can create transitional instability and impact financial reporting oversight during the vacancy period.
📋 Key Facts
- David Silberman resigned from his roles as CFO, Treasurer, and Secretary on May 10, 2024.
- The resignation is effective July 12, 2024.
- The stated reason for departure is 'personal reasons'.
- The company has officially initiated a search process to appoint a new CFO.
Oramed Pharmaceuticals reported receiving a $9.6 million prepayment from Scilex Holding Company pursuant to the terms of a Senior Secured Promissory Note. This payment reduces the upcoming June 21, 2024 installment requirement.
🚩 Red Flags
- Ongoing reliance on prepayments from a single counterparty (Scilex) to meet significant upcoming debt obligations.
📋 Key Facts
- Received an additional payment of approximately $9.6 million on May 2, 2024.
- The payment is part of a Senior Secured Promissory Note with Scilex Holding Company for a principal amount of $101,875,000.
- The $9.6 million prepayment reduces the June 21, 2024 installment from $20 million to approximately $10.4 million.
- The payment was triggered by Scilex's receipt of net cash proceeds from debt or equity financing (70% mandatory prepayment clause).
Oramed Pharmaceuticals reported the receipt of early principal payments totaling $15 million from Scilex Holding Company. These payments are part of a larger $101.875 million Senior Secured Promissory Note issued in September 2023.
🚩 Red Flags
- Risk mentioned in forward-looking statements regarding 'Company's ability to receive payment of principal due pursuant to the Note'.
📋 Key Facts
- Received an early payment of $11.5 million on March 14, 2024.
- Received an early payment of $3.5 million on March 18, 2024.
- Total early payments received in March: $15 million.
- The second scheduled principal payment of $15 million was due on March 21, 2024; the company effectively satisfied this via the early payments.
- A third principal payment of $20 million is expected on June 21, 2024.
- The total principal amount of the Note is $101,875,000.
Oramed Pharmaceuticals Inc. announced the appointment of Yehuda Reznick to fill an existing vacancy on its Board of Directors, effective April 1, 2024. Mr. Reznick will also serve as the chair of the audit committee and has been designated as a 'financial expert'.
📋 Key Facts
- Yehuda Reznick appointed to fill an existing vacancy on the Board of Directors.
- Effective date of appointment: April 1, 2024.
- Mr. Reznick will serve as chair of the audit committee and is designated as a 'financial expert'.
- Reznick's background includes serving as an audit partner at Kesselman & Kesselman (PwC member) from 1999 to 2014.
- Remuneration for Mr. Reznick will be consistent with other non-executive directors.
Oramed Pharmaceuticals entered into a new $75 million 'at the market' (ATM) offering agreement with Rodman & Renshaw LLC and StockBlock Securities LLC. Simultaneously, the company terminated its previous $100 million controlled equity offering agreement with Cantor Fitzgerald.
🚩 Red Flags
- The use of an ATM offering often indicates a need for immediate liquidity to fund operations or R&D.
- Switching from one equity offering provider (Cantor Fitzgerald) to another (Rodman & Renshaw/StockBlock) can sometimes signal dissatisfaction with previous terms or a shift in financing strategy.
📋 Key Facts
- Entered into an ATM Agreement on March 18, 2024, for up to $75,000,000 in common stock.
- Agents for the new agreement are Rodman & Renshaw LLC and StockBlock Securities LLC.
- The company will pay a cash commission of up to 3.0% on gross proceeds from sales under the new ATM agreement.
- Terminated the Cantor Fitzgerald Controlled Equity Offering Agreement effective March 17, 2024.
- Previously raised approximately $26.25 million in net proceeds via the terminated Cantor Fitzgerald agreement.
Oramed Pharmaceuticals Inc. filed an 8-K to announce the issuance of a shareholder letter from CEO Nadav Kidron via press release.
📋 Key Facts
- The filing was made on February 20, 2024.
- The primary content is a shareholder letter authored by CEO Nadav Kidron.
- The announcement was disseminated via a press release (Exhibit 99.1).
Oramed Pharmaceuticals entered into a Joint Venture Agreement with Hefei Tianhui Biotech Co., Ltd. to develop and commercialize products based on Oramed's oral insulin and POD™ technology. The JV aims to initiate Phase 3 oral insulin trials in the US, leveraging HTIT's manufacturing capabilities.
🚩 Red Flags
- Consummation is contingent upon several ancillary agreements (asset transfer, commercial supply) due within 3 months.
- The deal includes a significant transfer of Oramed's core intellectual property to the JV.
- Risk that transactions may be more expensive or fail to close as anticipated.
📋 Key Facts
- Joint Venture (JV) established with Hefei Tianhui Biotech Co., Ltd. and its subsidiary Technowl Limited.
- Initial equity split is 50/50 between Oramed and HTIT.
- HTIT to contribute $70 million in cash; Oramed to contribute $20 million ($10M cash, $10M shares).
- Oramed will transfer intellectual property related to oral insulin and POD™ technology to the JV.
- Oramed is entitled to a 3% royalty on gross revenues generated from Oramed-related assets within the JV.
- HTIT has an option to invest up to an additional $20 million, which would increase its equity stake.
Oramed Pharmaceuticals Inc. announced the immediate resignation of Board member Yadin Rozov for personal reasons on January 17, 2024.
🚩 Red Flags
- Immediate departure of a Board member can sometimes signal internal friction, though not explicitly stated here.
📋 Key Facts
- Yadin Rozov resigned from the Board of Directors effective January 17, 2024.
- The resignation was for 'personal reasons'.
- Mr. Rozov stated he has no disagreement with the Company regarding its operations, policies, or practices.